Advisors Preferred LLC Sells 4,225 Shares of Moderna, Inc. (NASDAQ:MRNA)

Advisors Preferred LLC trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA) by 22.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,306 shares of the company’s stock after selling 4,225 shares during the period. Advisors Preferred LLC’s holdings in Moderna were worth $601,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in MRNA. MassMutual Private Wealth & Trust FSB increased its position in shares of Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after purchasing an additional 389 shares during the period. Blue Trust Inc. increased its holdings in shares of Moderna by 53.1% during the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock worth $47,000 after buying an additional 388 shares in the last quarter. EMC Capital Management raised its position in Moderna by 311.2% in the fourth quarter. EMC Capital Management now owns 1,250 shares of the company’s stock valued at $52,000 after purchasing an additional 946 shares during the last quarter. Larson Financial Group LLC increased its position in Moderna by 53.5% in the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after acquiring an additional 317 shares during the period. Finally, Rakuten Securities Inc. raised its stake in shares of Moderna by 477.3% during the third quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock valued at $63,000 after acquiring an additional 778 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Trading Down 3.0 %

Shares of MRNA opened at $32.60 on Friday. The stock’s 50-day simple moving average is $40.22 and its 200 day simple moving average is $58.87. Moderna, Inc. has a 52-week low of $31.94 and a 52-week high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter last year, the firm posted ($1.39) EPS. The company’s revenue was up 3.8% compared to the same quarter last year. Research analysts forecast that Moderna, Inc. will post -8.95 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders have sold 2,664 shares of company stock worth $115,210. 15.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

MRNA has been the topic of several recent research reports. Barclays cut their target price on Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. UBS Group lowered their price objective on shares of Moderna from $108.00 to $96.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. HSBC raised Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research note on Monday, November 18th. Wolfe Research started coverage on Moderna in a report on Friday, November 15th. They issued an “underperform” rating and a $40.00 target price on the stock. Finally, Argus downgraded shares of Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Four investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Moderna presently has an average rating of “Hold” and a consensus price target of $67.26.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.